Isosceles Pharmaceuticals

Isosceles Pharmaceuticals

Early Stage

Helping Solve America's Opioid Crisis

Helping Solve America's Opioid Crisis

Overview

Raised this Round: Raised: $5,000,000

Total Commitments ($USD)

Platform

Equifund

Start Date

10/03/2022

Close Date

04/30/2023

Min. Goal
$20,000
Max. Goal
$5,000,000
Min. Investment

$500

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.05

Pre-Money Valuation

$30,800,000

Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

Medtech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Wilmington, North Carolina

Business Type

Growth

Isosceles Pharmaceuticals, with a valuation of $30.8 million, is raising funds on Equifund CFP. It is a pharmaceutical company currently developing intravenous formulations of synthetic Cannabidiol as non-addictive alternatives to opium-based painkillers. The CBD formulations will be used for acute post-operative pain and will address the surgical population in the US, Europe, and the UK. Isosceles Pharmaceuticals is currently in the pre-clinical trials stage. Brett Lanier founded Isosceles Pharmaceuticals in April 2019. The current crowdfunding campaign has a minimum target of $20,000 and a maximum target of $5 million. The campaign proceeds will be used to fund pre-clinical animal trials and IND filings for a new intravenous drug delivery system.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$879,786

$891,911

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$212,834

$198,240

Accounts Receivable

$0

$0

Total Assets

$212,834

$198,240

Short-Term Debt

$0

$0

Long-Term Debt

$120,000

$0

Total Liabilities

$120,000

$0

Financials as of: 10/03/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Isosceles Pharmaceuticals on Equifund CFP 2022
Platform: Equifund
Security Type: Equity - Common
Valuation: $30,800,000
Price per Share: $2.05

Follow company

Follow Isosceles Pharmaceuticals on Equifund CFP 2022

Buy Isosceles Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Isosceles Pharmaceuticals may no longer be accepting investments.

Isosceles Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Isosceles Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Isosceles Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Isosceles Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge